English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 905873      Online Users : 507
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/7925


    Title: Programmed death-1 ligand mrna levels may predict survival and relapse in non-small cell lung cancer
    Authors: Wu, YH;Lee, MC;Chen, CY;Lee, H
    Contributors: Division of Environmental Health and Occupational Medicine
    Abstract: Background: Programmed death-1 ligand (PD-L) involved in PD-1/PD-L1 pathway has been shown to associate with tumor progression via suppression of T-cell immunity. However, the prognostic value of PD-L1 in non-small cell lung cancer (NSCLC) remains unclear, especially in human papillomavirus (HPV)-infected lung cancer. Methods: Two hundred and twenty one lung tumors surgically resected from NSCLC patients were enrolled to determine PD-L1 mRNA expression by real-time RT-PCR. HPV 16/18 E6 expression in lung tumors was examined by immunohistochemistry. The role of E6 on PD-L1 expression was examined by E6-knockdown and E-overexpression in HPV16 E6-positive lung cancer cells. Kaplain-Meier and Multivariate Cox regression analysis were used to verify whether PD-L1 mRNA levels may predict overall survival (OS) and relapse free survival (RFS) in NSCLC, especially in patients with E6-positive tumors. Results: PD-L1 mRNA levels in E6-positive TL-1 and TL-2 cells were remarkably higher than E6-negative A549, H23, H1355, TL-4, TL-5, TL-6 lung cancer cells. PD-L1 expression was decreased in E6-knockdown TL-1 and TL-2, and increased in E6-overexpression A549 and TL-4 cells compared with their control cells. Patients with low PD-L1 mRNA levels had poorer OS and RFS than those with high PD-L1 mRNA levels. Among patients with high PD-L1 mRNA levels, the hazard ratio (HR) of E6-positive patients was elevated to 1.89 (95% CI, 1.17-2.66, P = 0.003) compared with that of E6-negative patients (HR, 1.31, 95% CI, 1.07-1.58, P = 0.007). Conclusion: PD-L1 mRNA levels may predict survival and relapse in NSCLC. We suggest that PD-L1 may be a potential immunotherapeutic target in NSCLC, especially in patients with HPV infection.
    Date: 2011-06
    Relation: Journal of Thoracic Oncology. 2011 Jun;6(6):S667-S668.
    Link to: http://dx.doi.org/10.1097/01.JTO.0000399289.73317.3d
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1556-0864&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000208855803075
    Appears in Collections:[李輝(2009-2011)] 會議論文/會議摘要

    Files in This Item:

    File Description SizeFormat
    ISI000208855803075.pdf30518KbAdobe PDF552View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback